Ensayos clínicos

8.676 ensayos encontrados

Activo, no reclutaFase 2ClinicalTrials.gov

A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

INTERVENTIONALInicio: 28 de nov de 2019ID: NCT04179032

CompletadoFase 3ClinicalTrials.gov

A Two Week Randomized, Double Blind Placebo Controlled, Parallel Group Study of GW685698X Aqueous Nasal Spray 100mcg and 50mcg QD in Pediatric Subjects With Perennial Allergic Rhinitis

INTERVENTIONALInicio: 1 de feb de 2005ID: NCT00108914

ReclutandoClinicalTrials.gov

Real-world Evidence of First-line Treatment With Pediatric-like Protocol for Adolescents and Young Adults Patients Diagnosed With Philadelphia-negative Acute Lymphoblastic Leukemia

OBSERVATIONALInicio: 1 de mar de 2021ID: NCT05127148

CompletadoClinicalTrials.gov

The Accuracy of Pediatric Air Test as a Non-invasive Atelectasis Diagnostic Tool: a Multi-centre Prospective Double-blind Study

INTERVENTIONALInicio: 10 de sept de 2020ID: NCT04506203

CompletadoFase 3ClinicalTrials.gov

Study 200622: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Adolescent and Adult Subjects With Severe Hypereosinophilic Syndrome

INTERVENTIONALInicio: 7 de mar de 2017ID: NCT02836496

CompletadoFase 3ClinicalTrials.gov

6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected Once Daily in Children and Adolescents Age 6 - 17 Years With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period

INTERVENTIONALInicio: 14 de abr de 2016ID: NCT02735044

CompletadoFase 3ClinicalTrials.gov

A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL

INTERVENTIONALInicio: 1 de may de 2008ID: NCT00684177

CompletadoFase 2ClinicalTrials.gov

A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus

INTERVENTIONALInicio: 7 de sept de 2012ID: NCT01649765

ReclutandoFase 4ClinicalTrials.gov

An Open-label, Single-arm Study to Provide Continued Access to Study Drug to Participants Who Have Completed Pediatric Clinical Studies Involving Gilead HIV Treatments

INTERVENTIONALInicio: 27 de ago de 2024ID: NCT06337032

TerminadoFase 3ClinicalTrials.gov

A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin

INTERVENTIONALInicio: 11 de jun de 2014ID: NCT02131272

CompletadoClinicalTrials.gov

Implementation Fidelity and Benefits of the Critical Care Pediatric Guideline Adherence and Outcomes Program in Traumatic Brain Injury

INTERVENTIONALInicio: 9 de sept de 2019ID: NCT03896789

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus

INTERVENTIONALInicio: 10 de ene de 2025ID: NCT06739122

Aún no reclutaFase 3ClinicalTrials.gov

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 Diabetes

INTERVENTIONALInicio: 4 de ago de 2026ID: NCT07282613

ReclutandoFase 3ClinicalTrials.gov

A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II

INTERVENTIONALInicio: 21 de jul de 2022ID: NCT05371613

ReclutandoClinicalTrials.gov

A Multi-national Real-world Outcomes and Treatment Patterns Study of Lanadelumab (Takhzyro) in Paediatric Patients With Hereditary Angioedema (TAHORA)

OBSERVATIONALInicio: 5 de feb de 2026ID: NCT07251933

CompletadoFase 3ClinicalTrials.gov

One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study

INTERVENTIONALInicio: 21 de jun de 2018ID: NCT03560466

Activo, no reclutaFase 3ClinicalTrials.gov

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

INTERVENTIONALInicio: 21 de abr de 2025ID: NCT06921759

CompletadoClinicalTrials.gov

Evaluation of an Emergency Obstetric and Neonatal Care (EmONC) Intervention Package to Reduce Adverse Pregnancy Outcomes in Low Resource Settings (The EmONC Trial)

INTERVENTIONALInicio: 1 de dic de 2008ID: NCT01073488

ReclutandoFase 3ClinicalTrials.gov

A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

INTERVENTIONALInicio: 21 de jul de 2021ID: NCT04877288

CompletadoFase 3ClinicalTrials.gov

A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy

INTERVENTIONALInicio: 28 de sept de 2016ID: NCT02500381